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The exceptionally high virulence of the West Nile NY99 strain makes its suitability in the development of a live WN vaccine uncertain. The
aim of this study is to investigate the immunogenicity of noninfectious virus derivatives carrying pseudolethal mutations, which preclude virion
formation without affecting preceding steps of the viral infectious cycle. When administered using DNA immunization, such constructs initiate an
infectious cycle but cannot lead to a viremia. While the magnitude of the immune response to a noninfectious replication-competent construct was
lower than that of virus or infectious DNA, its overall quality and the protective effect were similar. In contrast, a nonreplicating construct of
similar length induced only a marginally detectable immune response in the dose range used. Thus, replication-competent noninfectious constructs
derived from infectious DNA may offer an advantageous combination of the safety of noninfectious formulations with the quality of the immune
response characteristic of infectious vaccines.
© 2006 Elsevier Inc. All rights reserved.Keywords: West Nile; 956D117B3 isolate; Infectious DNA; Pseudolethal mutations; Vaccine antibody; Neutralization; NY99 strain; MouseIntroduction
With more than 20,000 infections and more than 700 deaths
reported (Editorial, 2005), NY99 is regarded as the most
virulent West Nile (WN) strain known to date. It is estimated
that one to two million people have been infected (Editorial,
2005). Development of vaccines and therapeutics to control
WN-induced disease continues to be an urgent priority. The task
is challenging because the exceptionally high virulence of the
circulating NY99 strain makes its attenuation problematic.
Currently licensed antiviral vaccines may be subdivided in
two broad categories, infectious and noninfectious vaccines
(Murphy and Chanock, 1996). Although infectious vaccines are
known to induce a balanced long-lasting immune response (i.e.,
both humoral and cell-mediated), such vaccines always pose a
threat of uncontrolled infection. Noninfectious vaccines com-
posed of either a completely inactivated whole pathogen or its⁎ Corresponding author. Fax: +1 785 864 5294.
E-mail address: yaximik@ku.edu (V. Yamshchikov).
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doi:10.1016/j.virol.2006.07.038major immunogen(s) pose little or no risk of infection. Aside
from the need for multiple immunizations, noninfectious
vaccines are often much less effective in the induction of
CTL response (Ennis et al., 1999; Yamshchikov et al., 2005),
which plays a major role in clearing viral infection (Rothman et
al., 1998; Whitton and Oldstone, 1996).
A generalized virus infectious cycle includes three phases:
virus entry, intracellular replication, and virus assembly/release.
For simplicity, one may assume that for inactivated virus
vaccines, the cycle is interrupted at the first phase and for
infectious (live attenuated) vaccines, the cycle is affected in the
middle phase. Notably, there are no vaccines available in which
the last phase of the cycle is interrupted. Mutations ablating the
last phase can be defined as pseudolethal, since intracellular
replication may remain unaffected and the virus is not
completely inactivated. Such virus derivatives, if comparably
immunogenic, could combine benefits of infectious vaccines
with the safety of noninfectious formulations. Studies in this
direction depend on both the availability of molecular infectious
clones, which permit direct genome manipulation and on
Fig. 1. WN infectious DNA and its derivatives used in this study. A schematic
representation of the WN virus genome with genes of recognized virus-specific
proteins (Lindenbach and Rice, 2001) is shown at the top. The intron inserted at
pos. 358 is marked by a filled arrowhead. Deletion boundaries and deleted aa
sequences are indicated below each construct. CMV—human cytomegalovirus
promoter/enhancer, δ—antisense hepatitis δ ribozyme, BG—bovine growth
hormone transcription termination and polyadenylation sequence. For clarity,
the schematic is not drawn to scale.
116 A. Seregin et al. / Virology 356 (2006) 115–125available methods of delivery, which permit initiation of the
intracellular replication cycle.
Studies utilizing replicons of (+)RNA viruses (Anderson et
al., 1997; Caley et al., 1997; Fleeton et al., 1999, 2000, 2001;
Leitner et al., 1999, 2000; Moldoveanu et al., 1995; Novak et
al., 1999; Porter et al., 1997; Schlesinger and Dubensky, 1999;
Varnavski and Khromykh, 1999; Zhou et al., 1994) carrying
foreign antigens indicated that the replication competence of
vaccine vectors substantially enhances the immune response to
the delivered antigens. Encapsidated recombinant replicons are
capable of infecting cells and initiating a single round of
intracellular replication. However, the overall complexity of
encapsidation protocols decreases the practical value of the
approach. Genome RNA of (+)RNAviruses is infectious, which
permits the use of nucleic acid immunization for initiation of the
infectious cycle in vivo. Although as little as 1 ng of infectious
virus RNA (Mandl et al., 1998) or 100 ng of recombinant
replicon RNA (Ying et al., 1999) elicited antigen-specific
responses upon inoculation in mice, the vulnerability of RNA to
degradation undermines the practical importance of this
methodology. In this regard, the DNA/RNA layered approach
(Dubensky et al., 1996; Herweijer et al., 1995), which relies on
in vivo transcription of viral cDNA genome cassettes in host
cells to initiate the virus infectious cycle (hence, infectious
DNA or iDNA), appears more attractive and practical due to the
advantageous properties of DNA. Advantages include the
relative simplicity and low cost of DNA propagation,
straightforward quality control, the lesser vulnerability of
DNA to nuclease degradation and simplified storage and
transportation requirements.
The iDNA approach, however, has not been sufficiently
represented in studies on flavivirus vaccine development. This
is likely due to technical problems associated with the instability
of full genome flavivirus cDNA constructs during propagation
in E. coli, which is exacerbated when flavivirus genome cDNA
is positioned downstream from eukaryotic promoters. Recently
we reported a general approach to solve the problem (Mishin et
al., 2001; Yamshchikov et al., 2001a), which allowed us to
assemble stable iDNA constructs of attenuated W956 and
highly virulent NY99 strains (Borisevich et al., 2006). Further,
we prepared several constructs carrying pseudolethal mutations
that prevent assembly of the infectious progeny but otherwise
do not affect the preceding steps of the virus infectious cycle.
We analyzed these in detail and compared the immune
responses to an infectious virus, unmodified WN iDNA, and
its noninfectious replication-competent and nonreplicating
derivatives. In this report, we demonstrate that while infectious
virus and iDNA induce immune responses of a higher
magnitude than the uninfectious replication-competent deriva-
tive, the latter combines the advantage of unsurpassed safety
over infectious vaccines with higher immunogenicity and
protective potential over nonreplicating DNA vaccines. Most
importantly, the overall quality of the immune response induced
by the construct was found to be similar to both infectious virus
and iDNA. This evidence indicates that uninfectious replica-
tion-competent virus derivatives are worthy to be considered for
development of safe antiviral vaccines.Results
Construction of WN infectious DNA and its noninfectious
derivatives
DNA constructs used in the study are depicted in Fig. 1.
The parent iDNA construct pCMVWN has been described
earlier (Borisevich et al., 2006). Briefly, cDNA of attenuated
lineage 2 WN strain 956D117B3 (further abbreviated as
W956) (Yamshchikov et al., 2001b, 2004) was engineered in
pBR322 between the CMV promoter and the hepatitis δ
ribozyme, which is followed by the bovine growth hormone
transcription termination and polyadenylation (BG) sequence
as described earlier (Yamshchikov et al., 2001a). A 132-bp
chimeric intron is inserted at pos. 358 for stabilization of the
plasmid during routine propagation in E. coli (Yamshchikov et
al., 2001a).
A noninfectious replication-competent derivative of WN
iDNA, pCMVWN(ΔC), was created by PCR-mediated deletion
of a 48 nt fragment (pos. 226–273 of theWN genome, GenBank
#M12294) encoding amino acids 44 through 59, which compose
the α2 helix in the tertiary structure of the WN capsid protein
(Dokland et al., 2004). The rest of the construct is identical to
pCMVWN as was confirmed by complete sequencing of the
construct.
A noninfectious replication-incompetent construct
pCMVWN(ΔDD) was created by PCR-mediated deletion of 6
nucleotides (pos. 9673–9678) encoding D668 and D669 that are
part of the conserved GDD RNA polymerase motif in the WN
NS5 protein. This motif is highly conserved among RNA-
dependent RNA polymerases and deletion or mutation of this
sequence has been shown previously to eliminate replication of
Kunjin virus (Khromykh et al., 1998). Since replication of a
transcript originating from pCMVWN(ΔDD) was not expected,
δ ribozyme and BG were not included in this construct. We
determined that in the absence of BG a plasmid sequence
Fig. 3. Synthesis of WN-specific proteins in cells transfected with DNA
constructs used in this study. Nearly confluent monolayers of BHK cells were
either infected with W956, or transfected with corresponding DNA (as shown),
and lysed as described in Materials and methods. Lysates were resolved on 12%
SDS-PAAG, blotted onto nitrocellulose membranes and probed either with WN
specific HMAF (1:5000; panel A) or with WN-C-specific HMAF (1:1000, panel
B) and visualized using the DAB-peroxidase procedure. WN proteins identified
earlier (Yamshchikov and Compans, 1993; Yamshchikov and Compans, 1994;
Yamshchikov and Compans, 1995) are shown on the left. Amounts of lysates
shown in panel Awere normalized by the efficiency of transfection; amounts of
lysates in panel B were 1:1:5:10 (from left to right).
117A. Seregin et al. / Virology 356 (2006) 115–125positioned approximately 350 nt downstream from the end of
WN cDNA serves as a transcription terminator (results not
shown). Thus, as compared to RNA originated from replication-
competent pCMVWN and pCMVWN(ΔC), a transcript pro-
duced from pCMVWN(ΔDD) was expected to include addi-
tional vector-derived ∼350 nt at its 3′-end. Due to the presence
of the stop-codon normally terminating WN ORF at the end of
the NS5 gene, this extra sequence was not expected to modify
the construct's expression profile.
All the designed constructs were characterized by complete
sequencing of the entire WN cDNA inserts and have not
demonstrated any unexpected sequence changes.
Characterization of the infectious DNA and its derivatives in
tissue culture
Transient expression assays, immunohistochemical stain-
ing, and indirect immunofluorescence of transfected cells
were used to verify the functional integrity of the created
constructs. We demonstrated previously (Borisevich et al.,
2006) that in Vero or BHK cells the release of infectious
progeny can be detected 12 h post transfection (hpt) with
pCMVWN. Single WN antigen-positive cells were detectable
at 10 h after transfection in Vero cells using either
pCMVWN, pCMVWN(ΔC) or pCMVWN(ΔDD) (Fig. 2,
peroxidase-DAB staining), with no obvious difference among
constructs in the intensity of indirect immunofluorescence at
this time point (data not shown). While pCMVWN-trans-
fected monolayers demonstrated multicellular foci of virus
multiplication at 48 hpt, pCMVWN(ΔC)- and pCMVWN
(ΔDD)-transfected monolayers still displayed single cell
staining, indicating a lack of infectious progeny formation
(Fig. 2). At 48 hpt, the pCMVWN(ΔC)-transfected cells were
about three to five times more intense in fluorescence than the
pCMVWN(ΔDD)-transfected cells, demonstrating an inten-
sity similar or comparable to that observed in the pCMVWN-
transfected monolayers (results not shown). At 24 hpt,Fig. 2. Infectious properties of DNA constructs used in this study in tissue
culture. Nearly confluent Vero cell monolayers were transfected with
pCMVWN (panel wt), pCMVWN(ΔC) (panel ΔC) and pCMVWN(ΔDD)
(panel ΔDD) DNA and Lipofectamine 2000, fixed with 10% formalin at
specified time points after transfection (hpt) and immunostained with WN-
specific HMAF and the peroxidase-DAB procedure.production of WN-specific proteins in the pCMVWN-
transfected cells was comparable to that observed in W956-
infected cells as revealed by Western blot (Fig. 3A, detected
with WN-specific HMAF; Fig. 3B, detected with WN C-
specific HMAF), which agrees with an established productive
infectious cycle. In contrast, cells transfected with either
noninfectious construct produced less WN-specific proteins at
this time point, with a clear difference in protein amounts
between replication-competent pCMVWN(ΔC) and nonrepli-
cating pCMVWN(ΔDD) (Fig. 3). Amounts of cell lysates
loaded on gel shown in Fig. 3A were normalized by the
efficiency of transfection monitored by a β-galactosidase
assay after co-transfection with minute amounts of
pCMVβGal (Promega). For the Western blot shown in Fig.
3B, 5-fold more of pCMVWN(ΔC) and 10-fold more of
pCMVWN(ΔDD) lysates were loaded on the gel to confirm
production of ΔC and C.
[35S]-labeled WN-specific proteins present in the media 24
hpt (for the CMV-driven constructs) or 24 hpi (for W956)
were pelleted through a 20% sucrose cushion to separate
virions and subviral particles from soluble proteins (Mason et
al., 1991). Proteins from the media, from supernatants and
from pellets solubilized in RIPA buffer were recovered by
immunoprecipitation with anti-WN HMAF, resolved by SDS-
PAGE and visualized by autoradiography. All constructs
directed formation of a pelletable material, which in the case
of W956-infected and pCMVWN-transfected cells, demon-
strates the presence of all virion components, i.e., uncleaved
prM, E and C proteins (Fig. 4, lanes p). The 7-kDa M protein,
Table 1
Mice survival after inoculation of infectious DNA pCMVWN, replication-









10 3/12 25 6/6 100 6/6 100
1 3/12 25 6/6 100 6/6 100
0.1 7/12 58 6/6 100 6/6 100
0.01 10/12 83 6/6 100 6/6 100
0.001 11/12 92 6/6 100 6/6 100
0 0/6 100 – – – –
LD50=0.215 μg LD50 N/A
c LD50 N/A
c
a DNA dose, μg/mouse, i.m.
b Survival at 2 weeks after inoculation, S/T (Survived/Total).
c Cannot be calculated.Fig. 4. Characterization of proteins secreted from virus-infected or DNA-
transfected cells. Nearly confluent BHK cell monolayers were infected with
W956 or transfected with specific DNA (as shown), pulse-labeled with [35S],
chased and analyzed by centrifugation as described in Materials and methods.
WN-specific proteins were immunoprecipitated from the medium (lanes m),
supernatant (lanes s) or RIPA-solubilized pellets (lanes p) with WN-specific
HMAF. Known WN proteins are shown on the left. (pr)M denotes amino-
terminal 2/3 of prM that is cleaved during virion transport.
Fig. 5. Development of viremia in mice inoculated with indicated doses of virus
or infectious DNA. Groups of 4-week-old female mice were inoculated i.m. with
specified doses of W956 or pCMVWN and observed for 10 days. Small blood
samples were collected every other day and sera were frozen at −80 °C. Samples
from mice which survived until the end of the observation period (two per dose),
were titered individually as described in Materials and methods. Averaged
values are shown with error bars calculated as averaged deviations.
118 A. Seregin et al. / Virology 356 (2006) 115–125which remains embedded in the viral envelope after partial
cleavage of prM during virion transport (Lindenbach and Rice,
2001), was not present on the gel due to its small size; the
presence of glycosylated N-terminal fragment pr(M) in the
media and in supernatants (Fig. 4, lanes m and s) confirms the
occurrence of prM cleavage. Both pCMVWN(ΔC) and
pCMVWN(ΔDD) constructs directed the formation of sub-
viral particles, albeit in different amounts. These follow the
same secretory pathway as virions, as indicated by prM
cleavage, but lack capsids since C was not detected in the
pellets (Fig. 4, lanes p). The NS1 protein is also secreted from
the infected and transfected cells, but it is predominantly
found in the supernatant fraction (Fig. 4, lanes s); some NS1
recovered from the pellet fractions of W956 and pCMVWN
samples probably represents NS1 associated with cell debris
resulted from cytopathic effects (CPE) associated with
infection. Some amounts of prM and E remaining in the
supernatant likely originated from disrupted virions or subviral
particles.
Infectious properties of the recombinant plasmids
Infectious properties of pCMVWN were characterized in
Vero cells, which were transfected with iDNA complexed with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The specific
infectivity of pCMVWN was determined to be in the range of
3–5×106 pfu/μg, similar to that reported earlier for iDNA of
Japanese encephalitis virus (Yamshchikov et al., 2001a). In
agreement with immunohistochemical staining (Fig. 2), WN
virus was not detected in the media up to 12 h after transfection
with pCMVWN, but subsequently reached titers similar to
those observed in W956-infected cells (data not shown). No
infectious virus could be recovered from the media at any time
after transfection with either pCMVWN(ΔC) or pCMVWN
(ΔDD) constructs.To test the infectivity of iDNA constructs in mice, animals
were inoculated i.m. with 10-fold serial dilutions of
pCMVWN, pCMVWN(ΔC), or pCMVWN(ΔDD) and mice
were observed for 3 weeks for morbidity and mortality. Results
of the experiment are summarized in Table 1. While
unmodified infectious DNA pCMVWN remained infectious
in mice with LD50=215 ng, neither of the noninfectious
derivative constructs resulted in mouse mortality. Although
direct comparison cannot be made due to use of transfection
reagents in tissue culture, inoculation of mice with 215 ng of
pCMVWN appeared roughly equivalent to inoculation with
106 pfu of W956, with its LD50 of ∼106 pfu (Borisevich et al.,
2006; Yamshchikov et al., 2004). In an attempt to make a more
relevant comparison, we monitored the dynamics of viremia in
sera of mice after i.m. inoculation with 100 ng of pCMVWN or
with graded doses of W956. As shown in Fig. 5, dynamics of
viremia after inoculation of 100 ng of pCMVWN resembled
that observed after inoculation of 104 pfu of W956 but reached
a higher peak titer supporting the validity of the above
approximation.
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virus
Earlier we demonstrated that the immune response to
attenuated W956 (lineage 2) is highly cross-reactive with
NY99 (lineage 1) and efficiently protects animals against
challenge with NY99 (Yamshchikov et al., 2004). To
characterize immune response to pCMVWN infectious DNA,
we measured titers of NY99-reactive IgG in sera of survived
mice at 4 weeks after single inoculation with various doses of
infectious DNA. For averaging purposes, individual serum
samples in each dose group were combined and the averaged
sera were tested in ELISA and PRNT as described in Materials
and methods. For comparison, combined archival serum
samples, which were collected at 4 weeks after immunization
with graded doses of infectious virus W956 (Borisevich et al.,
2006), were measured in parallel in the same assays. Endpoint
dilution titers of the averaged sera determined by ELISA with
NY99 antigen are summarized in Table 2. The data further
support the strong immunogenicity of W956 reported earlier. A
similar strong NY99-cross-reactive immune response was
observed in animals immunized with pCMVWN, which is not
surprising given the similarity in dynamics of viremia shown in
Fig. 5. The higher peak viremia observed after inoculation with
100 ng of pCMVWN as compared to 104 pfu W956 agrees well
with the higher IgG titers observed in this dose range (Table 2).
Interestingly, while an increased dose of infectious DNA to
1 μg/mouse resulted in an increased immune response, the
further increase in the dose to 10 μg/mouse induced
substantially lower IgG titers. This reverse dose-dependent
effect was not observed after immunization with infectious
virus.
To compare qualitative parameters of immune responses to
infectious virus and infectious DNA, we analyzed immune sera
using isotype-specific ELISA. As shown in Table 2, both W956
and pCMVWN induced Th1-type immune responses, since
IgG2a/IgG1>1 was observed at all doses. While the immune
response after W956 immunization showed a stronger Th1 bias
as compared to pCMVWN as judged by the higher IgG2a/IgG1
ratios, in both immunization regimens the highest IgG2a/IgG1
ratios were associated with approximately equipotent doses ofTable 2
Characteristics of the immune response to infectious virus (WN) and infectious DN
W956
Dose a S/T b ∑IgG c,d IgG2a c IgG1 c 2a/1 e
1E+06 3/6 512,000 512,000 32,000 16
1E+05 4/6 512,000 1,024,000 32,000 32
1E+04 5/6 128,000 512,000 8000 64
1E+03 6/6 128,000 512,000 16,000 32
1E+02 6/6 8000 32,000 2000 16
a W956 dose, pfu/mouse, i.m.
b Number of survived mice, S/T (Survived/Total), 2 weeks after inoculation.
c Sera of survived mice, combined in each dose group at 4 weeks after inoculatio
d Total WN-specific IgG by ELISA; 4 weeks after inoculation.
e IgG2a/IgG1 ratio; 4 weeks after inoculation.
f pCMVWN dose, μg/mouse, i.m.104 pfu and 100 ng with a steady decrease on either side of the
optimal doses.
Immune response to the replication-competent construct
resembles that of infectious DNA
To evaluate the immunogenicity of the noninfectious
constructs in comparison to infectious DNA, serum samples
from mice that were inoculated with the graded doses of
pCMVWN, pCMVWN(ΔC), and pCMVWN(ΔDD) (Table 1)
were evaluated at 3 weeks post inoculation. No WN-specific
humoral immunity was detected in sera of pCMVWN(ΔDD)-
immunized mice at any dose. The magnitude of the immune
response to pCMVWN(ΔC) was still 3- to 6-fold lower as
compared to animals inoculated with similar doses of
pCMVWN (results not shown). Àt 3 weeks after the primary
inoculation, an approximately half of the survived animals in
the pCMVWN group, and all animals in the pCMVWN(ΔC)
and pCMVWN(ΔDD) groups were boosted with the same
doses of the same DNA construct. The remaining half of the
animals after single pCMVWN inoculation was observed for
another week and evaluated as described in the previous section.
As was seen after the primary inoculation, no morbidity or
mortality was observed for either noninfectious construct.
Morbidity and mortality also were not observed in the group
boosted with pCMVWN due to the immunity developed after
the primary inoculation, as evidenced by data shown in Table 2
for serum samples evaluated at 4 weeks after primary
immunization. Immune responses in groups were compared
4 weeks after the boost and are summarized in Table 3.
Interestingly, inoculation with the pCMVWN booster doses had
a largely negative effect with the exception of the low dose
groups (compare Tables 2 and 3). In contrast, the booster doses
of either noninfectious DNA resulted in a substantial increase in
titers of NY99-specific IgG (Table 3). Still, the nonreplicating
construct pCMVWN(ΔDD) was substantially inferior to
replication-competent pCMVWN(ΔC), demonstrating more
than 10-fold lower endpoint dilution titers even at the highest
dose range used.
The booster immunization with infectious DNA also
modified the Th1/Th2 ratio of the final immune responseA (pCMVWN)
pCMVWN
Dose f S/T b ∑IgG c,d IgG2a c IgG1 c 2a/1 e
10 3/12 64,000 128,000 32,000 4
1 3/12 512,000 128,000 16,000 8
0.1 7/12 256,000 256,000 8000 32
0.01 10/12 16,000 32,000 2000 16
0.001 11/12 4000 8000 500 16
n.
Table 3
Characteristics of the immune response to infectious DNA pCMVWN, replication-competent noninfectious pCMVWN(ΔC) and non-replicating pCMVWN(ΔDD)
Dose a pCMVWN pCMVWN(ΔC) pCMVWN(ΔDD)
S/T b ∑IgG c,d IgG2a c IgG1 c 2a/1 e S/T b ∑IgG c, d IgG2a c IgG1 c 2a/1 e S/T b ∑IgG c,d IgG2a c IgG1 c 2a/1 e
10 2/6 40,000 128,000 32,000 4 6/6 6400 6400 1600 4 6/6 400 400 ND N/A
1 2/6 80,000 64,000 16,000 4 6/6 6400 6400 3200 2 6/6 200 200 100 2
0.1 4/6 160,000 320,000 80,000 4 6/6 1000 1000 500 2 6/6 ND ND ND N/A
0.01 5/6 80,000 160,000 10,000 16 6/6 ND f ND ND N/Ag 6/6 ND ND ND N/A
0.001 6/6 2000 2000 500 4 6/6 ND ND ND N/A 6/6 ND ND ND N/A
a DNA dose, μg/mouse, i.m, immunization followed by a boost with the same dose at 3 weeks.
b Number of mice that survived the primary inoculation and the boost, S/T (Survived after the boost/Total before primary).
c Sera of survived mice, combined in each dose group at 4 weeks after the boost.
d Total WN-specific IgG by ELISA, 4 weeks after the boost.
e IgG2a/IgG1 ratio, 4 weeks after the boost.
f ND—not detectable.
g N/A—cannot be calculated.
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group where the booster immunization resulted in the increased
IgG titers with preservation of the Th1 bias (compare Tables 2
and 3). Both noninfectious constructs also demonstrated a Th1
bias, although much less pronounced based on the observed
IgG2a/IgG1 ratios. This agrees with characteristics of immune
response observed after i.m DNA immunization that are well
documented for a variety of DNA vaccines (Gurunathan et al.,
2000).
The protective efficacy of infectious DNA and its noninfectious
derivatives
Earlier we demonstrated highly protective effects of
immunization using W956 by challenging with highly virulent
NY99 (Borisevich et al., 2006; Yamshchikov et al., 2004).
Essentially similar NY99 neutralizing titers were observed in
mouse sera at 4 weeks after single immunization with infectious
DNA (Table 4). This evidence strongly suggested that iDNA
may have induced a similarly high protection against NY99
challenge. Indeed, with the exception of the lowest dose group,
the pCMVWN-immunized mice in all other dose groups were
completely protected against NY99 challenge (Table 5) even
after single inoculation of as little as 10 ng of pCMVWN.
Interestingly, the booster immunization with infectious DNA,Table 4
Development of NY99 neutralizing immunity after i.m. immunization of NIH Swis
Dose a S/T b W956 c, d Dose e S/T b pCMVWNc,d S/T f p
1E+06 3/6 320 10 1/6 320 2/6
1E+05 4/6 160 1 1/6 160 2/6 1
1E+04 5/6 80 0.1 3/6 320 4/6
1E+03 6/6 320 0.01 5/6 80 5/6
1E+02 6/6 40 0.001 5/6 20 6/6
a Virus dose, pfu/mouse, i.m.
b Number of survived mice, S/T (Survived/Total), 2 weeks after inoculation.
c Serum samples were combined for each dose group.
d Neutralizing antibody endpoint dilution titers 4 weeks after single immunization
e DNA dose, μg/mouse, i.m.
f Number of mice that survived the primary inoculation and the boost, S/T (Survi
g Neutralizing antibody endpoint dilution titers 4 weeks after the boost.
h ND-not detectable.while decreasing the titers of total NY99-specific IgG measured
by ELISA (Table 3), resulted in substantially increased serum
neutralizing titers (Table 4). All protected mice demonstrated no
signs of clinical infection. In contrast, 100% of mice in the
control group that were immunized with 10 μg of pBR322
(Table 5) succumbed to a fatal rapidly developing paralytic
encephalitis that is characteristic of NY99 infection (Borisevich
et al., 2006; Yamshchikov et al., 2004).
Despite demonstrating substantially lower total IgG and
neutralizing antibody responses as compared to infectious DNA
(Tables 3 and 4), the replication-competent noninfectious
derivative demonstrated excellent protection potency after
booster immunization, since 80% of all mice immunized with
pCMVWN(ΔC) withstood the challenge at 100% survival in
the three highest dose groups (Table 5). Even in the lowest dose
group, 33% of mice survived the challenge, an outcome close to
that observed in the group that was boosted with 1 ng of fully
infectious pCMVWN.
Even after the booster, pCMVWN(ΔDD) was substantially
less protective over the entire dose range used, which is in
agreement with substantially lower IgG and neutralizing titers.
Only 30% survival was observed among all mice immunized
with the replication-deficient construct and a maximum of 50%
survival was observed in the highest dose group that
demonstrated detectable neutralization titers (Tables 4 and 5).s mice with W956, pCMVWN, pCMVWN(ΔC) and pCMVWN(ΔDD)
CMVWNc,g S/T f pCMVWN(ΔC)c,g S/T f pCMVWN(ΔDD)c,g
640 6/6 40 6/6 40
280 6/6 160 6/6 NDh
640 6/6 ND 6/6 ND
160 6/6 ND 6/6 ND
20 6/6 ND 6/6 ND
.
ved after the boost/Total before primary).
Table 5
Survival of immunized mice after challenge with 10 LD50 of NY99
Dose a pCMVWN b pCMVWN c pCMVWN(ΔC) c pCMVWN(ΔDD) c pBR322 d
S/Te % S/Te % S/Te % S/Te % S/Te %
10 1/1 100 2/2 100 6/6 100 3/6 50 0/6 0
1 1/1 100 2/2 100 6/6 100 2/6 33
0.1 3/3 100 4/4 100 6/6 100 1/6 17
0.01 5/5 100 5/5 100 4/6 67 2/6 33
0.001 1/5 20 2/6 33 2/6 33 1/6 17
a DNA dose, μg/mouse, i.m.
b Mice were challenged 4 weeks after single immunization.
c Mice were challenged 4 weeks after the boost.
d Control group was challenged 4 weeks after immunization with 10 μg of pBR322.
e Survival at 2 weeks after challenge; (S/T)−Survived Challenge/Total after Immunization.
121A. Seregin et al. / Virology 356 (2006) 115–125Due to poor survival, the statistical significance of this
observation is uncertain.
Discussion
Attenuation remains a poorly understood process that is
unique for each virus. A safe level of attenuation is often
impossible to reach without risking a substantial loss of
immunogenicity or protective potency, especially for highly
virulent pathogens. ATh1-biased immune response is crucial for
a high efficacy and long-lasting protection, which is more
characteristic of attenuated live vaccines rather than of
noninfectious formulations (Ennis et al., 1999; Rothman et al.,
1998; Whitton and Oldstone, 1996; Yamshchikov et al., 2005).
While an increased availability of stable infectious clones and
better understanding of attenuation mechanisms undoubtedly
will open new approaches in the rational vaccine development,
the successful candidates remain dependent on their growth
capability. In this regard, infectious DNA of (+)RNA viruses
offers an array of benefits ranging from the advantageous
biochemical characteristics of DNA to a higher flexibility in
vaccine design and vaccine formulations, not to mention the
well-known Th1 bias of the immune response characteristic of
intramuscular DNA immunization. In this report, we compared
the immunogenicity of flavivirus infectious DNA with that of
homologous infectious virus and analyzed protective properties
of its noninfectious derivatives, which share a high safety profile
with noninfectious formulations.
The design of the replication-competent noninfectious WN
virus derivative considered in this study was based on the fact
that only the 5′-NTR including the N-terminal 20 aa of C, the
nonstructural protein genes from NS1 through NS5, and the
intact 3′-NTR are necessary and sufficient for replication of
flavivirus RNA (Khromykh and Westaway, 1997). We deleted a
part of the C gene that encodes one of four α-helices found in
the flavivirus capsid protein (Jones et al., 2003), thus abrogating
its ability to encapsidate RNA and form functional capsids. A
transcript produced from pCMVWN(ΔC) was replication-
competent without forming infectious progeny. This was
confirmed by indirect immunofluorescence, Western blot, and
plaque assays. Such types of mutations can be defined as
pseudolethal, because they affect only the late phase of the virusinfectious cycle, i.e., assembly of infectious virions. As
expected, the capsid-deficient construct directed release of
subviral particles (SVP) consisting of proteins prM/M and E
embedded in the viral envelope. The noninfectious pCMVWN
(ΔDD) construct that produces a replication-deficient transcript
was included as a genome-size control. The noninfectious
nature and the replication deficiency of this transcript was
ensured by lethal deletion in the NS5 gene and was also
confirmed by indirect immunofluorescence, Western blotting
and plaque assays. While lack of replication substantially
reduced protein levels, the construct also directed synthesis of
all WN-specific proteins, including formation and secretion of
subviral particles.
Formation and secretion of subviral particles have been
described both during productive flavivirus infection and upon
transfection of prM-E encoding constructs (Mason et al., 1991).
Subsequently, we and others have demonstrated that such
secretion also can be observed upon expression of longer
constructs, but depends on the presence of an active viral
protease (Lobigs, 1993; Yamshchikov and Compans, 1993,
1995). Both noninfectious genome size constructs pCMVWN
(ΔC) and pCMVWN(ΔDD) include intact NS2B-NS3 genes
(Fig. 1), which encode components of the virus-specified
protease (Rice, 1996).
The infectivity of flavivirus (Japanese encephalitis virus)
infectious DNA in tissue culture has been characterized earlier
(Mishin et al., 2001; Yamshchikov et al., 2001a); the specific
infectivity of WN infectious DNAwas found to be in the same
range of 3–5×106 pfu/μg. In this report we determined that WN
infectious DNA can also induce productive infection in mice
upon direct inoculation with i.m. LD50 of 215 ng. Comparison
of viremia initiated by infectious DNA and homologous virus
indicated that for attenuated W956, 100 ng of iDNA is
approximately as potent as 104–105 pfu of virus. This ratio
may depend on a variety of factors, such as route and method of
DNA inoculation, virulence of a parent strain, and other
parameters affecting virulence. As expected, both derivatives
that were not infectious in tissue culture also were not infectious
in mice, thus confirming the anticipated safety of these
constructs.
Immunization with pCMVWN resulted in a strong humoral
and neutralizing immune response even after only one i.m.
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of the immune response, such as a strong Th1 bias, was similar
to that induced by infectious virus suggesting that the ensuing
viral infection was a major inducing factor. However, the
effects of DNA immunization resulted in subtle differences in
the immune response that are not completely understood at
this time. For example, an apparent suppression of the humoral
immune response was observed with increased doses of
infectious DNA, and this was more pronounced after booster
immunization with the same doses. Since viremia remains a
crucial factor in the development of the immune response after
immunization with iDNA, this evidence likely reflects the
dichotomous nature of iDNA. Indeed, iDNA combines
properties of a DNA vaccine with a source of infectious
virus, and in the above scenario DNA immunization may have
a suppressive effect on ensuing viremia. This suggestion is
supported by the observation that the suppressive effect is
reduced at lower doses of infectious DNA. Such suppression
may be mediated by the innate immune response, which is
activated by unmethylated CpG motifs present in bacterially
produced DNA (Klinman et al., 1996) and stimulates the TLR-
9 receptor pathway (Hemmi et al., 2000). Activation of this
pathway results in rapid induction of IL-6, IL-12, and IFNγ by
B-, T-, and natural killer cells both in vitro and in vivo, which
peaks in 12 h (Klinman et al., 1996), i.e., before development
of detectable viremia. Immunosuppressive and immunostimu-
latory motifs (Gurunathan et al., 2000) present in the large
(>15 kb) plasmid carrying a mix of eukaryotic and prokaryotic
sequences may also contribute to the final outcome. Detailed
analysis of their effects is beyond the scope of this report and
is a matter of a separate study. More studies are needed to
better understand immune properties and the dichotomous
nature of infectious DNA that combines infectious properties
with characteristics of a DNA vaccine.
While the booster immunization with pCMVWN resulted in
a decrease in titers of NY99-specific antibodies detected by
ELISA and in some leveling of the observed Th1 bias as
compared to the single immunization regimen, it resulted in a
substantial increase of NY99 neutralization titers in sera of the
boosted mice. Further studies are needed to understand the basis
of this phenomenon. The observed outcome may relate to the
concept of “public” versus “personal” viral serotype quasis-
pecies and associated neutralizing immune responses (Hunziker
et al., 2003).
While inoculation with the replication-competent noninfec-
tious construct pCMVWN(ΔC) resulted in lower ELISA and
neutralizing titers as compared to infectious DNA and virus, the
complete lack of morbidity and mortality across the entire dose
range indicative of the high safety level of this construct,
constitutes an obvious advantage. The lower immunization
efficacy is likely associated with a low efficiency of DNA
delivery and may be substantially increased by improving DNA
uptake by cells, for example, using transfection-enhancing
formulations. Both noninfectious constructs directed production
of prM, E and the viral protease NS2B-NS3 that allowed the
formation and secretion of noninfectious subviral particles
(SVP) from transfected cells (Mason et al., 1991; Yamshchikovand Compans, 1993). These are antigenically similar to the
infectious virus and likely have contributed to an induction of
humoral responses. However, secretion of SVP was limited to
the number of cells initially transfected and was quantitatively
different from the exponential increase of virus and SVP
observed during productive infection. The replication compe-
tence of RNA transcripts produced by pCMVWN(ΔC) is an
important enhancing factor, because a much poorer immune
response was observed after immunization with the same
amounts pCMVWN(ΔDD) that produces a nonreplicating
RNA transcript. It must be mentioned, however, that the highest
dose used in this study (10 μg) was still substantially less than
the amount that is normally used for i.m. DNA immunization by
needle injection (50–100 μg) even in multiple immunization
regimens (Gurunathan et al., 2000). Yet, the replication-
competent construct was efficacious even at the 100- to 1000-
fold lower doses, not to mention that the infectious DNA
provided complete protection after inoculation with as little as
10 ng of DNA.
Recently, we demonstrated that W956-based chimeric
viruses carrying glycoproteins of NY99 demonstrate an
increased NY99-specific immunogenicity and protective effi-
cacy as compared to unmodified lineage 2 W956 (Borisevich et
al., 2006). These appear to be better candidates for development
of WN live vaccine. Such chimeric viruses retain the attenuated
phenotype of W956 (Yamshchikov et al., 2004), but require
further attenuation to achieve the safety level suitable for use in
animals and humans. While attenuation of NY99 would provide
a more efficacious vaccine candidate, the high virulence of this
strain poses tremendous challenges. In this report, we tested an
attractive approach that is based on noninfectious virus
derivatives with engineered pseudolethal mutations. CMV-
driven infectious DNA of NY99 recently became available
(Borisevich et al., 2006), which after the introduction of
modifications similar to described in this report, may yield an
exceptionally safe NY99 vaccine candidate. Undoubtedly,
additional studies are required to increase DNA uptake after
inoculation. Alternatively, using the gene gun or a similar
biolistic immunization approach may substantially increase the
efficiency of DNA immunization. We are in the process of
testing these alternatives.
Materials and methods
Viruses and cell culture
Vero cells (ATCC CRL-1586) and BHK-21 cells (Breden-
beek et al., 1993) were maintained at 37 °C in a humidified
atmosphere containing 5% CO2 in Dulbecco's modified Eagle
medium (DMEM) supplemented with 5% FetalClone III (FCIII;
Hyclone, Logan UT) and 1× antibiotic–antimycotic mixture
(Invitrogen, Carlsbad, CA). A 385-99 isolate of the NY99 strain
was provided by Dr. R. Tesh (UTMB, Galveston TX) at Vero
passage 1; a viral stock was prepared in Vero cells and titered as
described previously (Yamshchikov et al., 2004). The lineage 2
isolate W956 was described earlier (Yamshchikov et al., 2001b,
2004).
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10–12 g (3–4 weeks old) NIH Swiss outbred female mice
were purchased from Harlan Spraque-Dawley (Indianapolis,
IN). Mice were maintained in a BL3 facility according to the
NIH guidelines and used in experiments in accordance with an
IACUC-approved animal protocol.
Recombinant DNA constructs
Genetic engineering manipulations and PCR-mediated
mutagenesis were performed as described (Yamshchikov et
al., 2001a). The infectious clone of a lineage 2 WN virus
pSP6WN that was used as the parental clone in design of all
constructs described in this study has been reported earlier
(Yamshchikov et al., 2001b). Gel-purified fragments and
purified plasmids were sequenced using the ABI310 Genetic
Analyzer (ABI, Foster City, CA) and manufacturer's kits.
Contiguous sequences were assembled with AutoAssembler
2.0 software (ABI) and downstream sequence analysis was
done with the VectorNTI Advance suite (InforMax, Bethesda,
MD).
Antisera
Preparation of WN-HMAF was described previously
(Yamshchikov et al., 2001b). For preparation of WN C-
HMAF, mice were immunized i.p. at 3-week intervals with
3×100 μg with recombinant His6-tagged W956 C protein
produced in E. coli using the ProEX bacterial expression system
(Gibco-BRL, Bethesda, MD) followed by purification using Ni-
chelate chromatography in denaturing conditions and refolding
by dialysis. The obtained antiserum recognized W956 C protein
on Western blot, but was not reactive in immunoprecipitation in
nondenaturing conditions. An immune ascites fluid from the
immunized mice was prepared as described (Karu, 1993).
Protein analysis
BHK cells in 6-well plate clusters (75–80% confluent) were
transfected with 2 μg of plasmid DNA in the presence of
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer's protocol. After overnight incubation at 37 °C, transfected
cells were pulsed with 100 μCi of 35S labeling mix (EasyTag,
Perkin-Elmer, Boston, MA) for 1 h, washed and chased at 37 °C
in 2 ml of the growth media for 5 h (Yamshchikov et al., 1997).
One half of each media sample was mixed with a 1/10 vol of
RIPA buffer (Yamshchikov et al., 1997) and used for
immunoprecipitation as below. The other half was diluted to
9 ml with PBS, loaded on top of a 2 ml cushion of 20% sucrose
in PBS and centrifuged in a SW41 rotor at 25,000 rpm for 3 h at
5 °C. The supernatant was mixed with a 1/10 vol of RIPA buffer
and subjected to immunoprecipitation as below. The pelleted
material was resuspended in 500 μl of RIPA buffer. Immuno-
precipitation was done using the WN-specific hyperimmune
mouse ascites fluid (WN-HMAF) and protein A agarose (Vector
Laboratories) as described previously (Yamshchikov et al.,1997). Proteins were separated using 12% SDS-PAGE and
visualized by autoradiography.
For Western blot analysis, BHK cells infected with W956 at
MOI=10 were harvested 24 h post infection, pelleted and lysed
in Laemmli SDS sample buffer at 95 °C for 10 min. Cells
transfected with plasmids as above were harvested 24 h after
transfection and were processed in a similar manner. Protein
content in diluted lysates was measured either by Bradford or
DC assays using corresponding kits (Bio-Rad Laboratories)
according to the manufacturer's protocols. The transfection
efficiency was normalized by assaying for β-galactosidase
produced from minute amounts of co-transfected pCMVβGal
(Promega). Proteins separated using 12% SDS-PAGE were
transferred onto nitrocellulose membranes using semi-dry
electroblotting. After blocking with 4% BSA overnight at
4 °C, the membranes were incubated in 1:5000 or 1:1000
dilutions of WN-HMAF or C-HMAF, respectively, in 2% BSA
for 1 h followed by a goat anti-mouse IgG peroxidase conjugate
(Sigma) at 1:30,000 dilution in 2% BSA for 1 h. Three 10-min
washes in Tris-buffered saline with 0.05% Tween 20 were
included between each step. Protein bands were visualized by
chemiluminescence using SuperSignal West Pico kit (Pierce,
Rockford, IL). Film images were digitized using a Gel Logic
100 imaging system and the accompanying 1D software
(Kodak, Rochester, NY).
Immunization
Plasmid DNA for inoculation of mice was purified using
Qiagen EndoFree Plasmid Maxi kit (Qiagen, Valencia, CA); the
residual endotoxin content was within limits specified by the
manufacturer as determined using the LAL assay kit (Associates
of Cape Cod, MA). DNA for inoculation was dissolved in PBS
at 100 μg/ml, followed by serial 10-fold dilutions with pBR322
as carrier to maintain a constant overall DNA concentration. 5
groups of 6 mice were inoculated in the Tibialis interior muscle
(i.m.) with serial dilutions of each construct DNA. Groups 1, 3,
and 4 received pCMVWN, pCMVWN(ΔC), and pCMVWN
(ΔDD), respectively, and were boosted with the same doses of
the respective constructs 3 weeks later. Group 2 received only
one injection with infectious DNA pCMVWN. A control (group
5) of six mice was inoculated with 10 μg of pBR322. Mice were
challenged i.m. with 10 LD50 of NY99 at 4 weeks after the
inoculation (group 2) or after the boost (groups 1, 3, 4 and 5).
For evaluation of immune responses, mice were bled at 3 and
4 weeks post immunization, at 3 and 4 weeks post boost, and
3 weeks post challenge (survivors). During the experiment,
mice were observed daily for morbidity and mortality;
moribund mice were euthanized and scored as fatal cases.
Evaluation of virus-specific humoral immune responses
Following immunization, titers of virus-specific IgG were
determined using indirect ELISA as described earlier (Yamsh-
chikov et al., 2004). Briefly, the coating antigen consisted of
NY99 virus that was pelleted through a 20% sucrose cushion
and solubilized in 50 mM triethanolamine–HCl pH 8.5,
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supernatant (1000×g, 15 min, 4 °C) was used for coating at a
dilution of 1:400 in PBS. To obtain averaged results, individual
serum samples in each dose group were combined for the same
time points and the combined averaged sera was tested in
ELISA and PRNT. Serial 2-fold dilutions of sera were tested in
duplicate using a goat anti-mouse IgG peroxidase conjugate
with the TMB substrate (Sigma-Aldrich, St. Louis, MO).
Samples were read at 450 nm using a PowerWave XS
microplate reader equipped with KC-4 software (Bio-Tek,
Winooski, VT). Readings of two standard deviations above the
background (serum from negative control mice used at the same
dilution) were considered positive. IgG1 and IgG2a titers were
determined in a similar procedure with goat anti-mouse IgG1-
peroxidase or goat anti-mouse IgG2a-peroxidase conjugates
(Southern Biotechnology Associates Inc., Birmingham, AL) as
secondary antibody in ELISA.
NY99 neutralizing antibody titers were determined in PRNT
assays done as described previously (Yamshchikov et al., 2004,
2005). The endpoint serum dilutions that gave a 50% reduction
in foci compared with control wells containing no immune
serum were counted positive.
For comparison, combined serum samples collected earlier
after immunization with graded doses of infectious virus W956
(Borisevich et al., 2006; Yamshchikov et al., 2004) were
measured in parallel in the same assays.
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